Ritholtz Wealth Management Buys 39,386 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Ritholtz Wealth Management increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 80.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 88,228 shares of the biopharmaceutical company's stock after purchasing an additional 39,386 shares during the period. Ritholtz Wealth Management's holdings in Gilead Sciences were worth $8,150,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of GILD. nVerses Capital LLC bought a new position in shares of Gilead Sciences during the 3rd quarter valued at about $25,000. Valued Wealth Advisors LLC boosted its stake in Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 161 shares in the last quarter. Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences during the second quarter valued at approximately $33,000. Cedar Wealth Management LLC lifted its holdings in shares of Gilead Sciences by 51.6% in the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 160 shares during the last quarter. Finally, Friedenthal Financial bought a new stake in shares of Gilead Sciences in the 3rd quarter worth approximately $50,000. 83.67% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares of the company's stock, valued at $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 456,234 shares of company stock valued at $42,130,461 over the last three months. Insiders own 0.29% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on GILD shares. Mizuho lifted their target price on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an "outperform" rating in a research report on Thursday, November 21st. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a report on Thursday, November 7th. Cantor Fitzgerald reissued a "neutral" rating and issued a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Maxim Group lowered Gilead Sciences from a "buy" rating to a "hold" rating in a research report on Friday, November 8th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and issued a $84.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $97.96.

Gilead Sciences Stock Up 0.2 %

Shares of NASDAQ:GILD traded up $0.19 during trading on Friday, reaching $91.84. 6,852,085 shares of the stock traded hands, compared to its average volume of 6,737,253. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90. The stock has a market cap of $114.46 billion, a P/E ratio of 1,020.44, a price-to-earnings-growth ratio of 1.27 and a beta of 0.18. The stock has a 50-day moving average of $91.85 and a two-hundred day moving average of $83.81. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same quarter last year, the company earned $2.29 EPS. The company's quarterly revenue was up 7.0% compared to the same quarter last year. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were paid a $0.77 dividend. The ex-dividend date was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.35%. Gilead Sciences's dividend payout ratio is presently 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.